In Monday’s session, Viridian Therapeutics Inc (NASDAQ:VRDN) marked $16.19 per share, up from $15.88 in the previous session. While Viridian Therapeutics Inc has overperformed by 1.95%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VRDN fell by -29.27%, with highs and lows ranging from $39.00 to $10.93, whereas the simple moving average fell by -27.82% in the last 200 days.
On June 14, 2023, Credit Suisse started tracking Viridian Therapeutics Inc (NASDAQ: VRDN) recommending Outperform.
Analysis of Viridian Therapeutics Inc (VRDN)
Further, the quarter-over-quarter decrease in sales is -93.97%, showing a negative trend in the upcoming months.
Viridian Therapeutics Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -62.57% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 13.93, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and VRDN has an average volume of 731.42K. On a monthly basis, the volatility of the stock is set at 8.08%, whereas on a weekly basis, it is put at 8.98%, with a gain of 15.73% over the past seven days. Furthermore, long-term investors anticipate a median target price of $38.57, showing growth from the present price of $16.19, which can serve as yet another indication of whether VRDN is worth investing in or should be passed over.
How Do You Analyze Viridian Therapeutics Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.96%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 86.25% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in VRDN shares?
The recent increase in stakes in VRDN appears to be a result of several institutional investors and hedge funds increasing their positions. Paradigm BioCapital Advisors LP’s position in VRDN has increased by 52.44% in the first quarter. The company now owns 3,681,747 shares of the stock, with a value of $46.02 million, following the purchase of 1,266,491 additional shares during the last quarter. Deep Track Capital LP made another increased to its shares in VRDN during the first quarter, upping its stake by 131.60%. During the last quarter, the company picked up 1,683,765 additional shares for a total stake of worth $37.04 million, bringing number of shares owned by the company to 2,963,267.
During the first quarter, SSgA Funds Management, Inc. added a 23,321 position in VRDN. BlackRock Fund Advisors sold an additional 34108.0 shares in the last quarter, decreasing its holdings by -1.25%, now holding 2.7 million shares worth $33.74 million. At the end of the first quarter, The Vanguard Group, Inc. decreased its VRDN holdings by -5.92% and now holds 2.35 million VRDN shares valued at $29.39 million with the lessened -0.15 million shares during the period. VRDN shares are owned by institutional investors to the tune of 86.25% at present.
